Navigation Links
Novel tuberculosis vaccine in Germany in clinical phase
Date:9/11/2008

For the first time in more than 80 years a promising live vaccine against tuberculosis has passed into the clinical phase in Germany: Since Monday of this week the new vaccine, which goes by the designation "VPM1002", has begun safety testing on volunteers in a Phase I clinical trial in Neuss, Germany. It is based on a highly safe vaccine that was introduced in 1921. However, the vaccine has been genetically developed to an extent where it is significantly more effective at preventing infection with tuberculosis bacteria than its predecessor. So far, VPM1002 has proved to be extremely effective and safe in animal models. This good protection now has to be proven in humans for the vaccine to be ready for the final approval," explains the Chief Executive Officer of Vakzine Projekt Management GmbH (VPM), Bernd Eisele.

VPM coordinates application-oriented development of vaccines. The organisation is a public-private partnership established by the Federal Ministry of Education and Research (BMBF) and Helmholtz Centre for Infection Research in 2002. We ensure that the outstanding results of basic science are actually used for the good of mankind and make their way into use," says the Clinical Project Manager Hans von Zepelin. In this, the superb contacts enjoyed by VPM within German science prove a great aid, as the Scientific and Technical Services Manager at the Helmholtz Centre for Infection Research, Rudi Balling, states: "VPM knows exactly where promising projects can be found. With their assistance we, the researchers, can show that our ideas are helping people to stay healthy."

With the financial support of the BMBF VPM was able to licence the novel tuberculosis vaccine from the Max Planck Institute for Infection Biology. The scientific foundation was established in this institute by its Founding Director Stefan H.E. Kaufmann. "The new vaccine is based on the most administered live-vaccine worldwide: Bacille Calmette-Gurin (BCG). However
'/>"/>

Contact: Hanner Schlender
hannes.schlender@helmholtz-hzi.de
49-531-618-11400
Helmholtz Association of German Research Centres
Source:Eurekalert  

0

GOOD

Page: 1 2

Related medicine news :

1. VCU Massey Cancer Center spearheads novel clinical study for lymphoma patients
2. Urigen Announces Issuance of Key Patent for URG101 - A Novel Therapy to Treat Painful Bladder Syndrome/Interstitial Cystitis
3. Bruker Daltonics Showcasing Novel Proteomics Solutions Based on Mass Spectrometry at the 7th HUPO World Congress 2008
4. NIH scientists find a novel mechanism that controls the development of autoimmunity
5. Sales of Emerging Novel Pain Therapies Will Represent More than One-Fifth of the Total Pain Drug Market by 2023
6. Novel Diagnostic Marker for Acute Kidney Injury Previewed at Abbott-Sponsored Scientific Workshop
7. Toyota Tsusho America, Inc. and Nippon Kayaku Co., Ltd. Announce the Formation of GlycoMark, Inc., a Joint Venture to Develop and Commercialize Novel Biomarkers for Diabetes
8. Finding suggests novel ways to boost vaccination or natural defenses
9. Novel hydrogel systems for dentin regeneration
10. HighPoint Solutions Develops Novel Incentive Compensation Plan for New Benign Prostatic Hyperplasia (BPH) Product
11. Novel model of osteosarcoma
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Novel tuberculosis vaccine in Germany in clinical phase
Novel tuberculosis vaccine in Germany in clinical phase
(Date:1/8/2009)... Va., Jan. 8 Today, the... along with several national leadership organizati...nciples of hospice care and protection of the Medi...ogether in sharing this unified message about end-...ce and Palliative Medicine, Hospice and Palliative...
(Date:1/8/2009)...sugar sitting on the surface of cancer cells are k...oth treating and stopping the spread of certain ty...ostate, breast, ovarian and lung, among others. A...he Gateway for Cancer Research, an Illinois-based ...Franco, M.D., Ph.D., and her co-workers at the Moo...
(Date:1/8/2009)...pts Prenatal Solution Key Factor in Decision for F...RLANDO, Fla., Jan. 8 All...LLC, one of the largest multi-specialty group prac... the Allscripts Enterprise(TM) Electronic Health R...cians in 18 offices across Central Florida. , ...
(Date:1/8/2009)... local dance students will dance to raise money fo...IS, Jan. 8 , , , WHO: ...show off their talent in the 3rd annual Dance, ...ance Arts Centre. The, event will..., Participants raise money throu...
Breaking Medicine News(10 mins):Health News:National End-of-Life Organizations Release Consensus Statement on Hospice, the Medicare Hospice Benefit, and Key Issues for the Future 2Health News:National End-of-Life Organizations Release Consensus Statement on Hospice, the Medicare Hospice Benefit, and Key Issues for the Future 3Health News:National End-of-Life Organizations Release Consensus Statement on Hospice, the Medicare Hospice Benefit, and Key Issues for the Future 4Health News:National End-of-Life Organizations Release Consensus Statement on Hospice, the Medicare Hospice Benefit, and Key Issues for the Future 5Health News:National End-of-Life Organizations Release Consensus Statement on Hospice, the Medicare Hospice Benefit, and Key Issues for the Future 6Health News:National End-of-Life Organizations Release Consensus Statement on Hospice, the Medicare Hospice Benefit, and Key Issues for the Future 7Health News:Novel prostate cancer vaccine taking aim at cancer cell 'sweet spot' 2Health News:Physician Associates, LLC Selects Allscripts Electronic Health Record to Connect and Automate 80 Physicians 2Health News:Physician Associates, LLC Selects Allscripts Electronic Health Record to Connect and Automate 80 Physicians 3Health News:Physician Associates, LLC Selects Allscripts Electronic Health Record to Connect and Automate 80 Physicians 4Health News:Dance With Courage to Benefit Camp Courage 2
...ity is certainly one of the risk factors associate...hospitalization and mortality. Time and again, man...p between body shape // and heart disease. With th...y be it is time, people to reshape themselves. Th...
...rtment of Health and Human Services (HHS) plans to...n people has come under strong criticism for the p... America and other critics who say that the stocks...t least 100 million vaccine stocks in order to eff...
...her it's triggered by the monotone of an instructo...at all ages and grade levels sometimes have troubl...nd a way to combat the sleepiness // and to keep s...sn't have anything to do with caffeine or high-sug...
... massive AIDS/HIV control drive, Chinese authoriti...bution at hotels and public entertainment places. ...ndoms // using a special fund created for the purp...aid on Thursday. The condoms will be distributed ...
Other Medicine News:Health News:Health and Human Services stockpiles 20 million bird flu Vaccines 2Health News:China To Distribute Free Condoms To Combat AIDS/HIV 2
(Date:1/3/2009)... , , , , ROSEMONT, Ill., Jan. 2...ging (MRI) is a growing technology providing an in...the evaluation of back pain according to an articl...American Academy of Orthopaedic Surgeons ( http://...ext several years, additional technical developmen...
(Date:12/29/2008)...BETHESDA, Md., Dec. 29 ...an Research Protection was announced today by Dr. ... Health Improvement Institute. , , The winner ... M.D. Anderson Cancer Center -- for its best pr...This program provides for 1) enhanced human subjec...
(Date:12/27/2008)... SAN DIMAS, Calif., Dec. 27 Acc...ers are best advised to consume modest doses of,r...as typically provided in 3,to 5 glasses of aged, ...(Photo: http://www.newscom.com/cgi-bin/prnh/2008...ws mega-dose resveratrol alone fails to prolong,t...
(Date:12/17/2008)...ificant milestone met in development and validatio... ASHLAND, Mass., Dec. 17 MatTek C...ic Advisory Committee (ESAC) endorsed the scientif...n Test (SIT) at its November meeting. ESAC conclu...ccuracy and reliability for the prediction of skin...
Breaking Medicine Technology:MRI Emerges As Vital Resource in Treatment of Back Pain 2MRI Emerges As Vital Resource in Treatment of Back Pain 32008 Human Research Protection Award Recipients Announced 2Longevity Seekers Advised to Consume Modest Doses of Red Wine Molecules in Dietary Supplements (Longevinex(R)) Rather than Mega-Dose Resveratrol Alone 2Longevity Seekers Advised to Consume Modest Doses of Red Wine Molecules in Dietary Supplements (Longevinex(R)) Rather than Mega-Dose Resveratrol Alone 3EpiDerm's Skin Irritation Test Fully Validated in European Union 2Poniard to Present Clinical Data From Picoplatin Trials in Multiple Tumor Types at American Society of Clinical Oncology 2008 Annual Meeting 2088 1Poniard to Present Clinical Data From Picoplatin Trials in Multiple Tumor Types at American Society of Clinical Oncology 2008 Annual Meeting 2088 2Poniard to Present Clinical Data From Picoplatin Trials in Multiple Tumor Types at American Society of Clinical Oncology 2008 Annual Meeting 2088 3Poniard to Present Clinical Data From Picoplatin Trials in Multiple Tumor Types at American Society of Clinical Oncology 2008 Annual Meeting 2088 4Poniard to Present Clinical Data From Picoplatin Trials in Multiple Tumor Types at American Society of Clinical Oncology 2008 Annual Meeting 2088 5MIT solves gravity defying bird beak mystery 3337 1MIT solves gravity defying bird beak mystery 3337 2MIT solves gravity defying bird beak mystery 3337 3UC San Diego nanostructures will raise thin film solar cell efficiency 5463 1UC San Diego nanostructures will raise thin film solar cell efficiency 5463 2Celebrex shows benefit in first of its kind lung cancer chemoprevention trial 19563 1Celebrex shows benefit in first of its kind lung cancer chemoprevention trial 19563 2Celebrex shows benefit in first of its kind lung cancer chemoprevention trial 19563 3
...abasis Therapeutics,Inc. (Nasdaq:MBRX), a biophar...opment and commercialization of novel drugs for th...lying unique,capabilities for targeting the liver ...rs were presented at the Endocrine Society,s,89th ...rovide data on MB07811, the Company,s,liver-target...
...able to two widely used diabetes medicines , , ...n 33,000 type 2 diabetes patients in a real-world,... the incidence of,hospitaliations for heart attack...rization for patients on Avandia is the,same as ...ere,released in a paper titled “Coronary Hea...
Other Medicine Technology:Metabasis Therapeutics Presents Results of Preclinical Studies for,MB07811, Its Novel Product Candidate for the Treatment of,Hyperlipidemia, at the Endocrine Society's Annual Meeting 2Metabasis Therapeutics Presents Results of Preclinical Studies for,MB07811, Its Novel Product Candidate for the Treatment of,Hyperlipidemia, at the Endocrine Society's Annual Meeting 3Metabasis Therapeutics Presents Results of Preclinical Studies for,MB07811, Its Novel Product Candidate for the Treatment of,Hyperlipidemia, at the Endocrine Society's Annual Meeting 4Newly Published Data from Large Study Support Cardiovascular Safety,of Avandia (Rosiglitazone Maleate) 2Newly Published Data from Large Study Support Cardiovascular Safety,of Avandia (Rosiglitazone Maleate) 3Newly Published Data from Large Study Support Cardiovascular Safety,of Avandia (Rosiglitazone Maleate) 4
Provide 1.5mm protection throughout. Six durable, attractive vinyl coverings are available. Lead glass window factory installed. Larger window available.
Swing-Arm™ Scatter Shield® provides lower extremity protection for personnel close to the tube. 24"Wx32"L lead shield swings 180 along table. Ideal for cardiac cath, special studies, electr
Front Protection with attached Belt Guard, Built-in Back Support; Buckle Closure
Surgical Drop-Off Apron
Medicine Products: